XSTOXSPRAY
Market cap140mUSD
Dec 23, Last price
42.00SEK
1D
-0.94%
1Q
-12.50%
IPO
27.27%
Name
XSpray Pharma AB (publ)
Chart & Performance
P/E
—
P/S
—
EPS
—
Div Yield, %
0.00%
Shrs. gr., 5y
13.40%
Rev. gr., 5y
-47.34%
Revenues
0k
Net income
-180m
L+37.92%
CFO
-203m
L+84.50%
Earnings
May 21, 2025
Profile
Xspray Pharma AB (publ), a pharmaceutical company, develops protein kinase inhibitors for targeted cancer treatments in Sweden. Its product candidates include HyNap-Nilo for the treatment of chronic myeloid leukemia; HyNap-Sora for the treatment of renal cancer and liver cancer, as well as several forms of thyroid cancer; and HyNap-Dasa for the treatment of chronic myeloid leukemia and acute lymphoblastic leukemia. The company was formerly known as Xspray Microparticles AB and changed its name to Xspray Pharma AB (publ) in 2017. Xspray Pharma AB (publ) was incorporated in 2003 and is based in Solna, Sweden.
Valuation
Title SEK in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|
| 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | 2016‑12 | 2015‑12 | |
| Income | |||||||||
Revenues | |||||||||
Cost of revenue | 42,779 | 141,352 | 105,821 | ||||||
Unusual Expense (Income) | |||||||||
NOPBT | (42,779) | (141,352) | (105,821) | ||||||
NOPBT Margin | |||||||||
Operating Taxes | (17) | (1,403) | 4 | ||||||
Tax Rate | |||||||||
NOPAT | (42,762) | (139,949) | (105,825) | ||||||
Net income | (179,667) 37.92% | (130,267) 34.71% | (96,702) 84.89% | ||||||
Dividends | |||||||||
Dividend yield | |||||||||
Proceeds from repurchase of equity | 298,446 | 100,761 | 105,862 | ||||||
BB yield | -28.06% | -8.31% | -8.51% | ||||||
| Debt | |||||||||
Debt current | 4,861 | 1,566 | 2,048 | ||||||
Long-term debt | 68,755 | 2,686 | 4,418 | ||||||
Deferred revenue | |||||||||
Other long-term liabilities | |||||||||
Net debt | (92,687) | (118,914) | (265,416) | ||||||
| Cash flow | |||||||||
Cash from operating activities | (203,275) | (110,179) | (51,607) | ||||||
CAPEX | (54,103) | (128,286) | (95,964) | ||||||
Cash from investing activities | (65,876) | (135,345) | (105,818) | ||||||
Cash from financing activities | 315,594 | 93,809 | 103,708 | ||||||
FCF | (104,654) | (159,952) | (107,757) | ||||||
| Balance | |||||||||
Cash | 166,303 | 120,166 | 271,881 | ||||||
Long term investments | 3,000 | 1,000 | |||||||
Excess cash | 166,303 | 123,166 | 271,882 | ||||||
Stockholders' equity | (523,471) | (351,401) | (221,731) | ||||||
Invested Capital | 1,253,692 | 907,488 | 815,140 | ||||||
ROIC | |||||||||
ROCE | |||||||||
| EV | |||||||||
Common stock shares outstanding | 26,594 | 21,263 | 19,413 | ||||||
Price | 40.00 -29.82% | 57.00 -11.08% | 64.10 -66.96% | ||||||
Market cap | 1,063,756 -12.23% | 1,211,971 -2.60% | 1,244,384 -63.07% | ||||||
EV | 971,069 | 1,093,057 | 978,968 | ||||||
EBITDA | (33,585) | (131,819) | (96,951) | ||||||
EV/EBITDA | |||||||||
Interest | 675 | 12 | 4 | ||||||
Interest/NOPBT | |||||||||